A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study is in two parts and will evaluate the safety, tolerability and efficacy of
escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination
with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation
study, at one of the following dose levels of ocrelizumab [400, 1000, 1500, and 2000
milligrams (mg)]. In Part 2, participants will be randomized to explore tolerability and
efficacy of doses which have been shown to be tolerated in Part 1.